HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer

Gichangi, Peter; Bwayo, Job J.; Estambale, Benson B.; Rogo, Khama; Njuguna, Esther; Ojwang, S. B. O.; Temmerman, Marleen

doi:10.1016/j.ygyno.2005.10.006

Cited by 54 publications

(62 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although concomitant HAART may lead to a greater likelihood of completing combined chemotherapy and radiation therapy, it does not in itself lead to regression of high-grade cervical dysplasia. 64,65 Current guidelines for cervical cancer screening by the USPSTF include women between 21 and 65 years old. Grade A recommendations include a Pap test every 3 years between 21 and 65 years old, or cytology with HPV testing every 5 years between 30 and 65 years old.…”

Section: Cervical Cancermentioning

confidence: 99%

Cancer screening in women living with HIV infection

Aboulafia

2017

Womens Health (Lond Engl)

View full text Add to dashboard Cite

The number of women living with HIV continues to increase. Thirty years into the AIDS epidemic, we now expect those with access to highly active antiretroviral to survive into their seventh decade of life or beyond. Increasingly, the focus of HIV care is evolving from preventing opportunistic infections and treating AIDS-defining malignancies to strategies that promote longevity. This holistic approach to care includes detection of malignancies that are associated with certain viral infections, with chronic inflammation, and with lifestyle choices. The decision to screen an HIV-infected women for cancer should include an appreciation of the individualized risk of cancer, her life expectancy, and an attempt to balance these concerns with the harms and benefits associated with specific cancer screening tests and their potential outcome. Here, we review cancer screening strategies for women living with HIV/AIDS with a focus on cancers of the lung, breast, cervix, anus, and liver.

show abstract

Section: Cervical Cancermentioning

confidence: 99%

Cancer screening in women living with HIV infection

Aboulafia

2017

Womens Health (Lond Engl)

View full text Add to dashboard Cite

show abstract

“…This may account for the more aggressive tumour behaviour, poor response to treatment and poorer prognosis, as demonstrated by several authors in HIV-positive patients, and which seems to relate to the degree of immune depletion. [11][12][13] Radiation and concomitant chemotherapy are common treatment modalities for patients with cervical cancer. These modalities can be used as primary treatment, adjuvant therapy after surgery, or therapy with palliative intent.…”

Section: Introductionmentioning

confidence: 99%

“…It has been suggested in several case series of HIV-positive patients treated for cervical and anal cancer that therapy is tolerable, but toxicity may be increased. 11,16,17 The current study compares the short-term outcome of HIVpositive patients who received radiation therapy and/or chemoradiation for cervical cancer, with that of HIV-negative patients. This retrospective study was performed in a public health facility which serves uninsured patients referred to the tertiary hospital following a diagnosis of invasive cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

The impact of HIV infection on women receiving radiation for cervical cancer

Mangena

Snyman

Dreyer

et al. 2015

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Background: The objective of the study was to compare patient characteristics, treatment toxicity and interruptions, and survival in human immunodeficiency virus (HIV)-positive and HIV-negative cervical cancer patients receiving radiation as primary or adjuvant treatment. Method:Demographics, clinical and tumour characteristics, and the outcomes of 51 HIV-positive and 47-HIV negative consecutive cervical cancer patients were assessed and compared, including co-morbidities, performance status, treatment type and toxicities, and survival.

show abstract

“…These authors reported 14% grade 3-4 GI toxicity while it was zero in our series. Our rate of ≥ grade 2 genito-urinary toxicity was 7.2% versus 18% in the TATA Memorial series..Positive HIV status increased the risk of developing multiple toxicities simultaneously (cutaneous, GI, genitourinary) and was an independent risk factor for discontinuation of treatment (HR=2.2 IC 95% 1.1-4.5), p=0.04) in the study published by Gichangi et al (2006). We described 32% of grade 3-4 leucopenia, very similar to the results of the prospective study by Simonds et al (2015) (31% versus 10% in the HIV negative population (p=0.003)).…”

Section: Toxicitymentioning

confidence: 56%

“…Gichangi et al (2006) showed that 19% of the patients had residual tumor at 4 and 7 months after EBRT. For these authors, a treatment duration longer than 50 days multiplied the risk of poor response by five (HR=4.4; CI 95% 1.8-13.3; p=0.001).…”

Section: Survivalmentioning

confidence: 99%

Outcomes after Radiation Therapy for HIV Positive Patients with Invasive Cervical Cancer

Molinier¹,

Huguet²,

Ballester³

et al. 2018

CCO

View full text Add to dashboard Cite

Objective: To assess tolerance, local control, and survival outcomes for HIV (human immunodeficiency virus) positive patients with locally advanced cervical cancer (CC) treated with external beam radiation therapy (EBRT) and/or brachytherapy from an Assistance Publique -Hôpitaux de Paris (APHP) retrospective cohort. Methods:Between 2000 and 2014, 28 HIV positive patients presenting with a non-metastatic CC were treated in one of the five APHP radiation therapy centers. Fifteen patients (54%) underwent primary surgery. Twenty-four patients (88%) received EBRT, with concurrent chemotherapy in 22 cases, and 68% received brachytherapy. Results:The median follow-up was 58 months. At 5 years, local control (LCR) and overall survival rates (OS) were 56% and 46.5% respectively. A grade 3-4 acute toxicity (mainly hematological toxicity) was reported in 18 patients (64%). In univariate analysis, total irradiation dose (p=0.03) and cisplatin-based chemotherapy (p=0.005) were predictive of acute toxicity. A grade 3-4 late toxicity (mainly gastro-intestinal and renal) was observed in 7 patients (25%). In univariate analysis, HIV stage at diagnosis (p=0.02) and an initial CD4 count <200/mm3 (p=0.03) were predictive factors of late toxicity. Conclusion:In this study including HIV positive patients with CC, local control and overall survival rates seemed to be lower than those reported in the literature for non-HIV patients. We also reported an increase in acute and late toxicity, mainly hematological, underlying the fundamental role of immunosuppression in tolerance to radiation therapy.

show abstract

HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer

Cited by 54 publications

References 43 publications

Cancer screening in women living with HIV infection

Cancer screening in women living with HIV infection

The impact of HIV infection on women receiving radiation for cervical cancer

Outcomes after Radiation Therapy for HIV Positive Patients with Invasive Cervical Cancer

Contact Info

Product

Resources

About